A citation-based method for searching scientific literature

T Heise, U Hövelmann, L Brøndsted, C L Adrian, L Nosek, H Haahr. Diabetes Obes Metab 2015
Times Cited: 78







List of co-cited articles
541 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
David Russell-Jones, Bruce W Bode, Christophe De Block, Edward Franek, Simon R Heller, Chantal Mathieu, Athena Philis-Tsimikas, Ludger Rose, Vincent C Woo, Anne Birk Østerskov,[...]. Diabetes Care 2017
84
32





Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Keith Bowering, Christopher Case, John Harvey, Michael Reeves, Michael Sampson, Robert Strzinek, Ditte-Marie Bretler, Rikke Beck Bang, Bruce W Bode. Diabetes Care 2017
48
35

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bruce W Bode, Joseph A Johnson, Liselotte Hyveled, Søren C Tamer, Marek Demissie. Diabetes Technol Ther 2017
42
33


Ultrafast-acting insulins: state of the art.
Lutz Heinemann, Douglas B Muchmore. J Diabetes Sci Technol 2012
55
23

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
Tim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, Jacob Bonde Jacobsen, Leszek Nosek, Eric Zijlstra, Hanne Haahr. Clin Pharmacokinet 2017
34
38

Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Chantal Mathieu, Bruce W Bode, Edward Franek, Athena Philis-Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell-Jones. Diabetes Obes Metab 2018
44
29

Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
Helena W Rodbard, Devjit Tripathy, Maricela Vidrio Velázquez, Marek Demissie, Søren C Tamer, Milivoj Piletič. Diabetes Obes Metab 2017
30
40


A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
Tim Heise, Ulrike Hövelmann, Eric Zijlstra, Kirstine Stender-Petersen, Jacob Bonde Jacobsen, Hanne Haahr. Drugs Aging 2017
15
66

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
11

Home Use of an Artificial Beta Cell in Type 1 Diabetes.
H Thabit, M Tauschmann, J M Allen, L Leelarathna, S Hartnell, M E Wilinska, C L Acerini, S Dellweg, C Benesch, L Heinemann,[...]. N Engl J Med 2015
255
11

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.
Hans J Woerle, Christoph Neumann, Silvia Zschau, Stephanie Tenner, Andrea Irsigler, Joerg Schirra, John E Gerich, Burkhard Göke. Diabetes Res Clin Pract 2007
204
11

Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Maryam Fath, Thomas Danne, Torben Biester, Lars Erichsen, Olga Kordonouri, Hanne Haahr. Pediatr Diabetes 2017
29
31

Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes.
Yoeri M Luijf, Arianne C van Bon, Joost B Hoekstra, J Hans Devries. Diabetes Care 2010
53
15

How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device.
Carsten Benesch, Tim Heise, Oliver Klein, Lutz Heinemann, Sabine Arnolds. J Diabetes Sci Technol 2015
27
29


Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
Eric Zijlstra, Marek Demissie, Tina Graungaard, Tim Heise, Leszek Nosek, Bruce Bode. J Diabetes Sci Technol 2018
22
36

Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Ananda Basu, Thomas R Pieber, Ann K Hansen, Stefanie Sach-Friedl, Lars Erichsen, Rita Basu, Hanne Haahr. Diabetes Obes Metab 2018
18
44

Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
Grit Andersen, Grégory Meiffren, Daniela Lamers, J Hans DeVries, Aymeric Ranson, Cyril Seroussi, Bertrand Alluis, Martin Gaudier, Olivier Soula, Tim Heise. Diabetes Obes Metab 2018
25
32

A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
David C Klonoff, Mark L Evans, Wendy Lane, Hans-Peter Kempe, Eric Renard, J Hans DeVries, Tina Graungaard, Agon Hyseni, Theis Gondolf, Tadej Battelino. Diabetes Obes Metab 2019
27
29





Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
L Heinemann, C Weyer, M Rauhaus, S Heinrichs, T Heise. Diabetes Care 1998
119
8

7
100


Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger. Diabetes 2004
409
8

Outpatient glycemic control with a bionic pancreas in type 1 diabetes.
Steven J Russell, Firas H El-Khatib, Manasi Sinha, Kendra L Magyar, Katherine McKeon, Laura G Goergen, Courtney Balliro, Mallory A Hillard, David M Nathan, Edward R Damiano. N Engl J Med 2014
336
8

Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes.
Richard M Bergenstal, Satish Garg, Stuart A Weinzimer, Bruce A Buckingham, Bruce W Bode, William V Tamborlane, Francine R Kaufman. JAMA 2016
300
8

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
John B Buse, Anders L Carlson, Mitsuhisa Komatsu, Ofri Mosenzon, Ludger Rose, Bo Liang, Kristine Buchholtz, Hiroshi Horio, Takashi Kadowaki. Diabetes Obes Metab 2018
24
29


Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.
Linda Morrow, Douglas B Muchmore, Marcus Hompesch, Elizabeth A Ludington, Daniel E Vaughn. Diabetes Care 2013
37
16

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
236
7

Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
E W ter Braak, J R Woodworth, R Bianchi, B Cerimele, D W Erkelens, J H Thijssen, D Kurtz. Diabetes Care 1996
98
7


Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
7

[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin.
D C Howey, R R Bowsher, R L Brunelle, J R Woodworth. Diabetes 1994
396
7

Insulin glulisine: a faster onset of action compared with insulin lispro.
T Heise, L Nosek, H Spitzer, L Heinemann, E Niemöller, A D Frick, R H A Becker. Diabetes Obes Metab 2007
58
10

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
Johannes Plank, Andrea Wutte, Gernot Brunner, Andrea Siebenhofer, Barbara Semlitsch, Romana Sommer, Sabine Hirschberger, Thomas R Pieber. Diabetes Care 2002
89
7


Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
Helle Linnebjerg, Eric Chen Quin Lam, Mary E Seger, David Coutant, Laiyi Chua, Chew Lan Chong, Maria M Ferreira, Danny Soon, Xin Zhang. Diabetes Care 2015
49
12



Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Richard M Bergenstal, David C Klonoff, Satish K Garg, Bruce W Bode, Melissa Meredith, Robert H Slover, Andrew J Ahmann, John B Welsh, Scott W Lee, Francine R Kaufman. N Engl J Med 2013
382
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.